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Abstract: Plasmodium falciparum malaria kills over
500,000 children every year and has been a scourge of
humans for millennia. Owing to the co-evolution of
humans and P. falciparum parasites, the human genome is
imprinted with polymorphisms that not only confer
innate resistance to falciparum malaria, but also cause
hemoglobinopathies. These genetic traits—including he-
moglobin S (HbS), hemoglobin C (HbC), and a-thalasse-
mia—are the most common monogenic human disorders
and can confer remarkable degrees of protection from
severe, life-threatening falciparum malaria in African
children: the risk is reduced 70% by homozygous HbC
and 90% by heterozygous HbS (sickle-cell trait). Impor-
tantly, this protection is principally present for severe
disease and largely absent for P. falciparum infection,
suggesting that these hemoglobinopathies specifically
neutralize the parasite’s in vivo mechanisms of pathogen-
esis. These hemoglobin variants thus represent a ‘‘natural
experiment’’ to identify the cellular and molecular
mechanisms by which P. falciparum produces clinical
morbidity, which remain partially obscured due to the
complexity of interactions between this parasite and its
human host. Multiple lines of evidence support a
restriction of parasite growth by various hemoglobinop-
athies, and recent data suggest this phenomenon may
result from host microRNA interference with parasite
metabolism. Multiple hemoglobinopathies mitigate the
pathogenic potential of parasites by interfering with the
export of P. falciparum erythrocyte membrane protein 1
(PfEMP1) to the surface of the host red blood cell. Few
studies have investigated their effects upon the activation
of the innate and adaptive immune systems, although
recent murine studies suggest a role for heme oxygenase-
1 in protection. Ultimately, the identification of mecha-
nisms of protection and pathogenesis can inform future
therapeutics and preventive measures. Hemoglobinopa-
thies slice the ‘‘Gordian knot’’ of host and parasite
interactions to confer malaria protection, and offer a
translational model to identify the most critical mecha-
nisms of P. falciparum pathogenesis.
Introduction
In the 4th century BC, Alexander the Great conquered the
known Western world [1]. Prior to his conquests in Asia, he
encountered the Gordian knot, a complex knot of bark affixing a
mythic ox-cart to a post in the town of Gordium. Alexander—a
pupil of Aristotle—set his mind to untangling the knot, but, like
others before him, could not find the ends (and thus the means) to
do so. Faced with this intractable problem, Alexander sliced
through the Gordian knot with a stroke of his sword and freed the
cart. As one of history’s greatest military commanders, Alexander
subsequently assembled and ruled an empire stretching from
the Eastern Mediterranean to the Himalayas while remaining
undefeated in battle. These military conquests were presaged by
his ‘‘Alexandrian solution’’ to the Gordian knot, demonstrating
decisiveness and imagination in the face of a complex and
seemingly unsolvable problem.
Malaria is an ancient disease that has persisted to our modern
age, intractably killing over 500,000 children in sub-Saharan
Africa each year [2]. While current interventions are succeeding in
reducing its morbidity in some contexts [3–5], further improve-
ments in our fundamental understanding of the pathogenesis of
Plasmodium falciparum malaria are clearly needed to identify the
molecular and cellular targets of next-generation therapeutics and
preventive measures. The mechanisms of falciparum malaria
pathogenesis remain obscure owing to the complex tangle of
parasite virulence factors, host susceptibility traits, and innate and
adaptive immune responses that modulate the development of
distinct malaria syndromes [6,7].
We propose that hemoglobinopathies slice the Gordian knot of
falciparum malaria pathogenesis to protect children from the
severe, life-threatening manifestations of the disease. Most
strikingly, heterozygous hemoglobin S (HbAS, or sickle-cell trait)
and homozygous hemoglobin C (HbCC, or hemoglobin C disease)
reduce the risk of severe falciparum malaria in sub-Saharan
African children by 90% and 70%, respectively [8]. These
structural hemoglobin variants do not protect from P. falciparum
infection [8], suggesting they interfere with the specific molecular
mechanisms responsible for the morbidity of falciparum malaria.
By isolating these pathogenic processes and solving the Gordian
knot of malaria pathogenesis, hemoglobinopathies offer an attractive
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‘‘natural experiment’’ to identify the molecular correlates of
clinical morbidity. These correlates may be amenable to exploi-
tation by future parasiticidal, adjunctive, or preventive therapies,
thereby yielding targets for a new ‘‘Alexandrian solution’’ to the
world’s falciparum malaria problem.
Here we review the proposed mechanisms by which hemoglo-
binopathies (and fetal hemoglobin) protect against falciparum
malaria.
The Red Blood Cell and Plasmodium falciparum
Parasites
The red blood cell (RBC) is critical for the propagation of
malaria parasites (Figure 1A). After inoculation into a human by a
mosquito and a brief, clinically silent incubation in the liver, P.
falciparum parasites enter the erythrocytic stage of their life-cycle. It
is during this time that parasites sequentially invade and egress
from their host RBCs and cause the signs and symptoms of
malaria. While developing within the RBC, the parasite traffics
proteins to the RBC surface that mediate binding to extracellular
host receptors and enable the parasite to sequester in the placenta,
brain, and virtually every other organ. The attenuation of malaria
by repeated, sub-lethal P. falciparum infections suggests a significant
role for adaptive immunity, but the targets of this attenuating
immune response remain largely obscure. Though this adaptive
immunity can be protective, the development of maladaptive and
dysregulated immune responses can also contribute to the
pathogenesis of malaria.
Variant RBCs are produced from some of the most common
human genetic polymorphisms, and for over 60 years their
Figure 1. General mechanisms by which hemoglobinopathies may attenuate the pathogenesis of falciparum malaria. (A) Restriction
of red blood cell (RBC) invasion or intraerythrocytic growth, thereby suppressing parasite densities in vivo; (B) interference with parasite-derived
mediators of pathogenesis, including those involved in the binding of parasite-infected RBCs (iRBCs) to extracellular host receptors; (C) modulation of
innate host defenses to favor protective, anti-inflammatory responses over those that drive pathogenic, pro-inflammatory responses; (D)
enhancement of adaptive cell-mediated and humoral immune responses that clear iRBCs from the blood.
doi:10.1371/journal.ppat.1003327.g001
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widespread prevalence has been hypothesized to result from their
evolutionary selection by severe, life-threatening falciparum
malaria [9]. This natural selection is supported convincingly by
clinical data for several common hemoglobin disorders (reviewed
in [8]). Hemoglobin is the oxygen-carrying component and major
protein of the RBC, and is normally formed as a tetramer of two
a-globins and two b-globins which constitute adult hemoglobin A
(HbA). The major hemoglobinopathies result from molecular
lesions that either decrease the production of a- or b-globins (in a-
and b-thalassemia, respectively) or encode single amino acid
substitutions in b-globin (in HbS, HbC, and hemoglobin E [HbE])
(Table 1) [10]. The most severe hemoglobinopathies—HbSS
homozygosity (sickle-cell disease) and the thalassemias major—are
typically incompatible with life beyond early childhood without
sophisticated medical care. Other hemoglobin traits such as
HbAS, HbAC, HbCC, HbAE, HbEE, and the thalassemias minor
are associated with essentially normal life-spans and far less
directly attributable morbidity. Remarkably, these simple poly-
morphisms confer dramatic levels of protection from a complex
disease: for HbAS, the substitution of glycine with valine at amino
acid position 6 in only one of two b-globin chains reduces a child’s
risk of severe falciparum malaria by about 90% [8].
The current understanding of falciparum malaria pathogenesis
suggests four general hypotheses for investigating the nature of
malaria protection by hemoglobinopathies (Figure 1): 1) restriction
of RBC invasion or intraerythrocytic parasite growth, 2) interfer-
ence with parasite-derived mediators of pathogenesis, 3) modula-
tion of innate host responses, and 4) enhancement of the host’s
adaptive immune clearance of parasite-infected RBCs (iRBCs).
While these mechanisms may be occurring simultaneously in vivo,
we review the evidence for each of them separately.
Do Hemoglobinopathies Restrict P. falciparum
Invasion of or Growth in RBCs?
Numerous investigations of the invasion and growth of P.
falciparum in RBCs containing variant hemoglobins rapidly
followed the development of in-vitro cultivation systems by Trager
and Jensen, and Haynes et al. in 1976 (Table 2) [11,12].
Reductions in RBC invasion have been reported for a variety of
hemoglobinopathies including a-thalassemia trait [13], HbH
disease [14,15], HbEE [13,15], HbAE [15], and the compound
heterozygous b-thalassemia/HbE disorder [13,15,16]; reductions
in the intraerythrocytic growth or maturation of parasites have
Table 1. The major hemoglobinopathies: epidemiology, molecular pathology, and clinical phenotype.
Hemoglobinopathy Epidemiology Genotype Molecular Pathology Clinical Phenotype
a-thalassemias
Trait
a+-thal trait Global Loss of one a-globin
gene (aa/a-)
Asymptomatic; normal RBC size,
quantity, and peripheral blood smear





Global Loss of three a-globin
genes (a-/–)
Accumulation of unpaired b-chains
that form HbH and precipitate in RBCs
Chronic hemolytic anemia with hepatic,
splenic, skeletal, and metabolic
sequelae; transfusion support required
in 2nd to 3rd decade of life
Hydrops fetalis/
Hb Barts
Global Loss of all four a-globin
genes (–/–)
Accumulation of unpaired c-chains
in utero, forming Hb Bart’s, which is
unable to release oxygen





of one b-globin gene
Typically asymptomatic; normal
hematocrit, low mean corpuscular
volume
Major Global Reduced expression
of both b-globin genes
Accumulation of unpaired a-chains,
leading to oxidant damage to RBCs
and erythroid precursors
Profound anemia leading to transfusion
dependence, complicated by iron
overload
Hemoglobin S Central, East, and
West Africa; Arabian
peninsula; South Asia
GluRVal at position 6
of b-globin
Aggregation of deoxygenated HbS into
polymers, leading to RBC deformation,
hemolysis, and microcirculatory
obstruction
Sickle-cell disease with frequent pain
crises, transfusions, and acute chest
syndrome when inherited as HbSS;
asymptomatic when inherited as HbAS
Hemoglobin C West Africa, centered
on western Burkina Faso
and northern Ghana
GluRLys at position 6
of b-globin
Formation of hexagonal HbC crystals Mild hemolysis and anemia when
inherited as HbCC; asymptomatic when
inherited as HbAC
Hemoglobin E Southeast Asia, centered
on border of Thailand,
Laos, and Cambodia
GluRLys at position 26
of b-globin
Mildly reduced expression of b-globin
due to insertion of splice site and
resulting mRNA degradation
Mild anemia, microcytosis, and
hypochromia
Hemoglobin Fa .50% of hemoglobin at
birth, largely absent by 6
months of age
Normal Tetramer consisting of two a-chains
and two c-chains
Greater oxygen affinity within RBCs
than adult hemoglobin A due to
attenuated interactions with 2,3-
bisphosphoglycerate
The human genome normally contains four copies of a-globin genes (in paired copies on chromosome 16: genotype aa/aa) and two copies of b-globin genes (on
chromosome 11). Normal adult hemoglobin (HbAA) is a tetramer of two a-globin and two b-globin proteins.
aNot technically a hemoglobinopathy but rather a normal hemoglobin variant of all newborns and infants.
doi:10.1371/journal.ppat.1003327.t001
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Table 2. Studies of P. falciparum invasion of and development in RBCs containing hemoglobin variants.
Hemoglobin, study Reference Parasite Invasion Development Note
a+-thal trait (aa/a-)
Friedman, 1979 [24] FCR-3 NR Normal Growth significantly attenuated by
cultivation at 30% O2
Ifediba et al., 1985 [14] NF-77 NR Normal
Bunyaratvej et al., 1992 [13] K1 Normal NR
Udomsangpetch et al., 1993 [48] TM267R Normal Reduced
a0-thal trait (aa/–)
Ifediba et al., 1985 [14] NF-77 NR Variably reduced
Luzzi et al., 1991 [105] IT NR Normal
Bunyaratvej et al., 1992 [13] K1 Reduced NR
Wiiliams et al., 2002 [106] A4U Normal Normal
HbH disease (a-/–)
Ifediba et al., 1985 [14] NF-77 Reduced Reduced
Brockelman et al., 1987 [16] T9/94 NR Reduced
Chotivanich et al., 2002 [15] TM267R, TAB106, TAM169, TAB183 Reduced NR
b-thalassemia minor
Friedman, 1979 [24] FCR-3 NR Normal Growth significantly attenuated by
cultivation at 30% O2
Brockelman et al., 1987 [16] T9/94 NR Reduced
Luzzi et al., 1991 [105] IT NR Normal
Bunyaratvej et al., 1992 [13] K1 Normal NR
HbSS
Friedman, 1978 [29] FCR-3 NR Normal Growth significantly attenuated by
cultivating HbAS and HbSS iRBCs
at low O2 tension
Pasvol et al., 1978 [17] Parasite isolates Increased Reduced Invasion and growth rates reduced
in HbSS iRBCs at low O2 tension
Pasvol, 1980 [18] Parasite isolates Increased Reduced Growth attenuated in HbSS iRBCs
at low O2 tension
LaMonte et al., 2012 [32] 3D7 NR Reduced
HbAS
Friedman, 1978 [29] FCR-3 NR Normal Growth significantly attenuated by
cultivating HbAS iRBCs at low O2
tension
Pasvol et al., 1978 [17] Parasite isolates Normal Reduced Invasion and growth rates reduced
in HbAS iRBCs at low O2 tension
Pasvol, 1980 [18] Parasite isolates Normal Normal Growth attenuated in HbAS iRBCs
at low O2 tension
LaMonte et al., 2012 [32] 3D7 NR Reduced
HbCC
Friedman et al., 1979 [19] FCR-3 NR Reduced
Olson & Nagel, 1986 [20] FCR-3 Normal Reduced Lysis of HbCC iRBCs was restricted,
preventing merozoite egress




Friedman et al., 1979 [19] FCR-3 NR Normal
Olson & Nagel, 1986 [20] FCR-3 Normal Normal
HbSC
Friedman et al., 1979 [19] FCR-3 NR Normal Growth significantly attenuated by
cultivating HbSC iRBCs at low O2
tension
Bunyaratvej et al., 1992 [13] K1 Normal NR
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been reported for HbH disease [14,16], b-thalassemia minor [16],
HbSS [17,18], HbAS [17], HbCC [19–21], HbEE [22], HbAE
[16], and HbF [23–26]. In addition to these positive findings,
conflicting data have been reported from many of these
investigations (see Table 2).
For HbS-containing RBCs specifically, several reports have
implicated enhanced sickling of iRBCs as a mechanism of malaria
protection. Luzzatto et al. [27] and Roth et al. [28] separately
reported increased sickling of HbAS iRBCs at low oxygen tension
compared to HbAA iRBCs. Similarly, Friedman [29] described
comparable parasite growth rates in HbAA, HbAS, and HbSS
RBCs at high oxygen tension (18%), but sickling and destruction
of parasites in HbAS and HbSS RBCs at lower oxygen tensions
(1%–5%) that more closely mimic the micro-aerophilic environ-
ment of post-capillary venules in vivo. Conversely, exposure of
iRBCs with either a- or b-thalassemia traits to high oxygen
tensions restricted parasite growth, suggesting a reduced ability to
tolerate oxidative stress [24].
A recent study proposes a novel mechanism of P. falciparum
growth inhibition in HbS-containing RBCs. Both HbAS and
HbSS RBCs manifest host microRNA (miRNA) profiles that are
distinct from those of HbAA RBCs [30,31]. Employing multiple
independent approaches, LaMonte et al. [32] describe the trans-
location of several host RBC miRNAs into P. falciparum parasites,
as well as the fusion of these human miRNAs with extant parasite
mRNA transcripts to subsequently inhibit the translation of
enzymes that are critical for parasite development. Specifically,
the host miRNAs miR-451 and let-7i were significantly more
abundant in HbAS and HbSS RBCs, and were associated with
attenuated parasite growth in these cells. In addition, the
inhibition of these two miRNAs by experimental transfection of
RBCs with antisense oligonucleotides partially restored parasite
growth. Downstream, miR-451 appears to fuse with transcripts of
the regulatory subunit of the parasite’s cAMP-dependent protein
kinase (PKA-R) to reduce its translation, thereby upregulating
activity of its substrate PKA and ultimately disrupting multiple
parasite developmental pathways. Thus, the aberrant miRNA
profile of HbS-containing RBCs may modulate the intraerythro-
cytic maturation of P. falciparum in a way that restricts parasite
growth.
Do Hemoglobinopathies Interfere with Intrinsic
Pathogenic Mechanisms of P. falciparum Malaria?
Two major pathogenic phenotypes of iRBCs have been
described: those that mediate binding of iRBCs to endothelial
receptors (‘‘cytoadherence’’) [33] and those that mediate binding
of iRBCs to uninfected RBCs (‘‘rosetting’’) [34,35]. Both
Table 2. Cont.
Hemoglobin, study Reference Parasite Invasion Development Note
HbEE
Nagel et al., 1981 [22] FCR-3 NR Reduced
Santiyanont & Wilairat, 1981 [115] FCR-1, FCM-1, K1 NR Normal No impact of high O2 tension
Bunyaratvej et al., 1992 [13] K1 Reduced NR
Chotivanich et al., 2002 [15] TM267R, TAB106, TAM169, TAB183 Mildly reduced NR
HbAE
Nagel et al., 1981 [22] FCR-3 NR Normal
Santiyanont & Wilairat, 1981 [115] FCR-1, FCM-1, K1 NR Normal No impact of high O2 tension
Brockelman et al., 1987 [16] T9/94 NR Reduced
Bunyaratvej et al., 1992 [13] K1 Normal NR
Chotivanich et al., 2002 [15] TM267R, TAB106, TAM169, TAB183 Reduced NR
b-thalassemia/HbE
Brockelman et al., 1987 [16] T9/94 Reduced NR
Bunyaratvej et al., 1992 [13] K1 Reduced NR
Udomsangpetch et al., 1993 [48] TM267R Normal Reduced
Chotivanich et al., 2002 [15] TM267R, TAB106, TAM169, TAB183 Reduced NR
HbF
Pasvol et al., 1976 [23] Parasite isolates Increased Reduced HbF RBCs derived from cord blood
of a patient with HbAA genotype
Pasvol et al., 1977 [25] Parasite isolates Normal Reduced HbF RBCs derived from newborns
with HbAA genotype and from
donors with HPFH
Wilson et al., 1977 [26] Parasite isolates Normal Reduced HbF RBCs derived from newborns
with HbAA genotype and from
donors with HPFH
Friedman, 1979 [24] FCR-3 NR Reduced
Amaratunga et al., 2011 [51] 7G8, GB4, MC/R+, FVO, TM284 Normal Normal HbF RBCs derived from cord blood
and from a donor with HPFH
Unless otherwise stated, assessments of RBC invasion and growth are relative to HbAA or non-thalassemic RBCs.
NR, not reported; HPFH, syndrome of hereditary persistence of fetal hemoglobin.
doi:10.1371/journal.ppat.1003327.t002
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adherence phenotypes are conferred by the expression of P.
falciparum erythrocyte membrane protein 1 (PfEMP1) [36–38], a
family of highly variant proteins that are concentrated in
protuberant structures called ‘‘knobs’’ on the iRBC surface.
Different PfEMP1 variants mediate the binding of iRBCs to
microvascular endothelial cells (via CD36, ICAM-1, etc.) [39],
placental syncytiotrophoblasts (via chondroitin sulfate A) [40,41],
and uninfected RBCs (via complement receptor 1, A and B blood
group antigens, and heparin sulfate-like antigens) [42–44]. Other
pathogenic mechanisms that may be associated with disease
include the production of cytokines in response to P. falciparum
glycosylphosphatidylinositol (PfGPI) [45] and parasite-derived uric
acid [46], direct hemolysis due to parasite egress from RBCs, and
PfEMP1-mediated suppression of inflammatory cytokines (dis-
cussed below) [47].
A series of investigations suggests that the weakening of
cytoadherence interactions partially governs malaria protection
by the hemoglobinopathies. Early studies by Udomsangpetch et al.
[48] described impaired rosetting and binding to human
umbilical-vein endothelial cells by a- and b-thalassemic iRBCs,
although many of these RBCs contained additional hemoglobin
mutations that may have influenced this phenotype. Additionally,
impaired rosetting and cytoadherence were not clearly associated
with reductions in the levels of surface antigens implicated in
binding interactions. Similarly, Fairhurst et al. [21] found that the
density of PfEMP1-laden knobs was markedly lower on the surface
of HbAC and HbCC iRBCs (compared to HbAA iRBCs) despite
comparable total iRBC levels of knob-associated histidine-rich
protein (KAHRP), a major parasite-produced component of
knobs. Further investigation of this phenomenon found that
HbAC and HbCC markedly impaired the binding of iRBCs to
human microvascular endothelial cells (HMVECs) under both
static and physiologic flow conditions [49]. Subsequent investiga-
tions also found significant reductions in the binding of HbAS
iRBCs [50], HbF-containing iRBCs [51], and a-thalassemic
iRBCs [52] to HMVECs. Taken together, these reports support
a common pathway for reducing the pathogenicity of parasites
infecting hemoglobinopathic RBCs, whereby aberrant surface
expression of PfEMP1 attenuates the binding of iRBCs to host
cells within microvessels [53].
A recent study supports this candidate mechanism of malaria
protection. Cyrklaff et al. [54] investigated the protein-trafficking
network of the iRBC and demonstrated that the parasite remodels
the RBC’s actin cytoskeleton to enable the export of parasite-
derived proteins to knobs on the iRBC surface. In HbSC and
HbCC iRBCs, this actin cytoskeleton is disrupted and the export
of parasite proteins to surface knobs is relatively inhibited, possibly
due to the inhibition of actin polymerization by hemichromes.
These forms of oxidized, denatured hemoglobin are known to
accumulate in HbS- and HbC-containing RBCs, thus providing a
potential link between hemoglobin instability and abnormal
PfEMP1/knob display. Further studies are needed to explore the
impact of this phenomenon upon both in-vitro measures of parasite
virulence—including PfEMP1 expression and iRBC binding to
host cells—and in-vivo measures of malaria severity.
Do Hemoglobinopathies Impact the Innate Host
Defense Responses to P. falciparum?
There is an emerging recognition of the impact of aberrant host
responses in the pathogenesis of malaria, particularly severe
falciparum malaria (reviewed in [55–57]). Studies of adjunctive
interventions to modulate this response in humans have not
yielded sustained successes [58], but experiments in murine
models continue to demonstrate benefit [59], and new modalities
remain under active investigation [58,60,61].
The innate host defense response encompasses myriad stereo-
typical pathways that are activated by microorganisms and
orchestrated to mitigate insults while minimizing collateral toxicity
(reviewed in [62]). Typically initiated by the recognition of
pathogen-associated molecular patterns (PAMPs) by Toll-like
receptors (TLRs) on leukocytes, these responses subsequently
progress through: 1) a pro-inflammatory phase marked by release
of cytokines, activation of endothelial cells, and recruitment of
circulating and locally resident immune effector cells; 2) a counter-
regulatory phase in which tissue-protective molecules such as
erythropoietin [63,64], heme oxygenase-1 (HO-1) [65,66], and
angiopoietin-1 [67] are deployed to limit inflammatory damage;
and 3) a repair phase mediated by vascular- and tissue-specific
stem cells [68,69]. These phases result from host and pathogen
factors that collectively balance these pro-inflammatory and
counter-regulatory responses.
In falciparum malaria, these innate immune responses are
potently initiated through the activation of TLRs on leukocytes by
both PfGPI [70] and hemozoin (the product of heme polymer-
ization) [71,72], as well as by microvascular inflammation caused
by PfEMP1-mediated binding of iRBCs to endothelium (see
above) [73]. In murine models, the outcome of malaria is sensitive
to experimental manipulation of multiple host innate response
molecules, such as tumor necrosis factor (TNF), interferon-c [74],
and erythropoietin [75], suggesting their role in mediating
differential infection outcome. In human studies, severe malaria
has been associated with increased angiopoietin-2, decreased
angiopoietin-1, and decreased endothelial nitric oxide levels [76–
78], and the upregulation of counter-regulatory molecules
including HO-1 and erythropoietin [78–80].
Few studies have investigated the impact of hemoglobinopathies
on these responses, though recent murine and human studies have
shed light on a possible role for HO-1. Normally, HO-1
catabolizes and thus mitigates the cytotoxicity of free heme, which
is released by the degradation of the RBC’s hemoglobin. Recent
studies in murine models identified HO-1 as a protective counter-
regulatory molecule in sepsis [81] and malaria [82,83]. In
addition, a recent study by Cunnington et al. has demonstrated
that when HO-1 is upregulated in response to hemolysis during
murine Plasmodium infection, resistance to non-typhoidal Salmonella
disease is abrogated [84]. In combining mouse models of human
cerebral malaria and of human sickle-cell trait, Ferreira et al. [85]
demonstrated that mice carrying RBCs with human HbS were
protected from cerebral malaria. Furthermore, they provided
evidence that this protection is associated with chronically elevated
production of HO-1 and with reduced production of inflammatory
cerebral chemokines during infection. However, the interpretation
that HO-1 activity may mediate HbS-associated protection from
malaria in mice is complicated by elegant recent work on severe
malaria in humans [86]. In Gambian children, the association of
HO-1 levels with severe malaria was variable, and HO-1 promoter
polymorphisms that confer higher constitutive levels of HO-1 were
associated with increased risk of severe malaria. These findings,
gathered mostly from patients with HbAA, suggest that HO-1 may
be either protective or deleterious across a wide spectrum of levels
in vivo.
Despite the paucity of investigations of hemoglobinopathies and
innate host defenses, a separate line of investigations of nitric oxide
(NO) and severe malaria highlights the importance of interactions
between iRBC and endothelium in the pathogenesis of severe
malaria. As noted above, severe falciparum malaria is associated
with low NO bioavailability [87,88], and a polymorphism in the
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nitric oxide synthase 2 (NOS2) promoter—which increases NO
production and is prevalent in Kenyan and Tanzanian children—
was associated with substantial protection from severe malaria
[89]. Data support diverse roles for NO in mediating parasite
death [90] and in acquiring immune memory [91]. NO also
manifests anti-inflammatory activity by reducing the expression of
host receptors used by iRBCs to bind microvascular endothelial
cells [92]. Indeed, the addition of NO to an in-vitro model of endo-
thelial binding downregulated the endothelial expression of
ICAM-1 and VCAM-1, and attenuated the cytoadherence of
iRBCs under flow conditions [93]. Thus, both hemoglobinopa-
thies and increased NO production are associated with protection
from severe malaria in vivo, and both are also associated with
reduced binding of iRBCs to endothelium in vitro. These findings
suggest that similar molecular phenomena—the disruption of
iRBC–endothelium interactions—may also occur in vivo.
Do Hemoglobinopathies Enhance the Adaptive
Immune Response to P. falciparum?
Evidence from field studies supports an association between
several hemoglobinopathies, adaptive immunity, and protection
from malaria [94,95], though investigations of these relationships are
complicated by the absence of reliable correlates of immune protection.
A central role for antibodies in malaria immunity is suggested
by the ability of polyclonal IgG from malaria-immune adults to
clear parasitemias in children with malaria [96]. Several field
studies have investigated differences in antigen seroreactivity in
children with hemoglobinopathies. Cross-sectional studies of
children with hemoglobinopathies in Nigeria [97], the Gambia
[98], Cameroon [99], Gabon [100,101], and Burkina Faso [102]
have yielded inconsistent results, with some demonstrating higher
seroreactivity to specific or variant surface P. falciparum antigens of
heterologous parasites in HbAS children, and others reporting no
differences. These findings were explored by measuring seroreac-
tivity to a panel of 491 P. falciparum proteins in Malian children
before and after a well-defined malaria transmission season [103];
though IgG responses to antigens were enhanced after the
transmission season, there were no qualitative or quantitative
differences in antigen recognition between HbAA, HbAS, and
HbAC children. Given the methodological strengths of this study
and the broad spectrum of antigens investigated, it seems clear that
these hemoglobinopathies do not generally enhance the acquisi-
tion of antibodies to P. falciparum antigens. It remains to be fully
investigated whether they enhance IgG recognition of specific
variants of PfEMP1 or other surface antigens that are known to
play a role in malaria immunity.
Antibody-mediated phagocytosis of iRBCs is believed to be an
important effector mechanism in protection from malaria.
Investigations with normal RBCs have demonstrated that mono-
cytes preferentially phagocytose iRBCs compared to uninfected
RBCs, and that this preference is potentiated by the binding of
IgG to iRBCs [104]. Additionally, polyclonal IgG from hyper-
immune sera binds more avidly to both a-thalassemic iRBCs
[105,106] and b-thalassemic iRBCs [105] compared to non-
thalassemic iRBCs, suggesting that this mechanism may prefer-
entially clear iRBCs harboring hemoglobin variants. Indeed, Ayi
et al. [107] demonstrated that ring-parasitized HbAS, b-thalasse-
mic, and HbH RBCs had higher levels of membrane-bound
hemichromes, C3c fragments, and aggregated band 3 proteins,
and were phagocytosed more readily than ring-parasitized HbAA
RBCs. While these data suggest that hemoglobinopathies func-
tionally enhance the clearance of iRBCs, the precise mechanism of
this enhancement remains obscure, evidence for this role in
parasite clearance by other hemoglobinopathies is lacking, and the
correlation between this mechanism and protection from clinical
disease has not been specifically investigated.
Multiple lines of evidence support the hypothesis that P.
falciparum parasites interfere with the acquisition of immunologic
memory responses that contribute to subsequent control of
parasitemia (reviewed in [108]). Several mechanisms are support-
ed by murine and human studies, including the depletion by
circulating parasites of dendritic cells [109], parasite-specific
CD4+ T cells [110,111], and memory B cells [112] by either
soluble factors [111] or interactions between iRBCs and antigen-
presenting cells [113]. It is unknown whether hemoglobinopathies
impact the efficiency or magnitude of the cellular and molecular
mechanisms that suppress immune memory directed at P.
falciparum parasites.
An Integrated Hypothesis
In this review, we have artificially partitioned the evidence for
diverse mechanisms of protection, but pathogenic pathways
overlap substantially, and it is similarly likely that protective
mechanisms in vivo also involve multiple pathways. As noted above,
field evidence indicates that hemoglobinopathies do not impair
parasite infection but instead attenuate malaria; this pattern
suggests that protection from malaria syndromes is not mediated
against the pre-erythrocytic stages of the P. falciparum life-cycle,
Box 1. Questions for future translational
investigations
1. Do microRNAs impact the maturation of parasites in
HbC, HbE, a-thalassemic, or HbF RBCs? Is their profile
or impact in HbAS RBCs modified by the presence of
a-globin deletions?
2. Does microRNA manipulation of HbS-containing iRBCs
impact their ability to cytoadhere to human microvas-
cular endothelial cells or rosette with uninfected RBCs?
3. How does the presence of a-thalassemia modify the
effects of HbS, HbC, or HbE on parasite growth,
maturation, microvascular adhesion, or endothelial
cell activation?
4. Do hemoglobinopathies quantitatively or qualitatively
restrict the expression of specific variants of PfEMP1?
5. Does reduced binding to human endothelial cells in
vitro correlate with reductions in markers of endothe-
lial activation in vivo?
6. How do other malaria-protective polymorphisms, such
as type O blood group antigen and glucose-6-
phosphate dehydrogenase (G6PD) deficiency, interact
with co-inherited hemoglobinopathies in mitigating
pathogenesis?
7. How do hemoglobinopathies impact the resting
endogenous levels of angiopoietin-1, angiopoietin-2,
and heme oxygenase-1?
8. Do hemoglobinopathies augment cell-mediated im-
munity to P. falciparum antigens?
9. Do hemoglobinopathies quantitatively or qualitatively
enhance the acquisition of antibodies to specific
variants or domains of PfEMP1?
10. Do hemoglobinopathies impair the mechanisms by
which the iRBC and the parasite interfere with the
acquisition of immune memory?
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and that hemoglobinopathies may influence the transition from
parasite infection to disease.
Embroidering the positive and negative evidence summarized
above suggests a model of malaria protection in which hemoglo-
binopathies impair the parasite’s trafficking of PfEMP1 and other
knob proteins to the iRBC surface [21], possibly due to the
association of hemoglobinopathies with elevated hemichrome
levels [49,54]. Abnormal PfEMP1/knob display weakens the
molecular interactions involved in the cytoadherence [49] and
rosetting [48,49] of iRBCs in microvessels. The attenuation of
these host–parasite interactions not only mitigates microvascular
obstruction and ischemia, but also impairs the activation of
endothelial cells and limits the elaboration of inflammatory
mediators including TNF [114]. Additionally, given the role of
PfEMP1 in downregulating the release of pro-inflammatory
cytokines like IL-12 [113] and IFN-c [47] from PBMCs, abnormal
PfEMP1/knob display may inhibit the parasite’s ability to blunt
both innate and adaptive immune responses. Finally, this
attenuation of host-cell injury, coupled with mechanisms of
parasite growth restriction in hemoglobinopathic iRBCs, may be
involved in prolonging the asymptomatic phase of parasitemia.
This delay in developing symptoms (and thus delay in seeking
antimalarial treatment) may offer a greater amount of time for
erythrocytic-stage antigens and markers of RBC senescence to be
exposed to the immune system, thereby enhancing both the
acquisition and maintenance of the adaptive and memory immune
responses that ultimately protect individuals from developing the
deadliest complications of P. falciparum infection. This model is
based upon currently available data largely obtained from in-vitro
experimental and in-vivo animal model studies, and most
commonly for HbAS and a-thalassemia. Clearly, many opportu-
nities exist to interrogate these phenomena in translational studies
involving human populations that carry diverse hemoglobinopa-
thies (Box 1).
Conclusions
In the spirit of Alexander, we propose that hemoglobinopathies
may be nature’s ‘‘Alexandrian solution’’ to the problem of
understanding fundamental aspects of falciparum malaria. This
bold slice through the Gordian knot of malaria pathogenesis
represents a unique opportunity to isolate and identify the
molecular correlates of falciparum malaria pathogenesis in
humans in vivo, and to translate these findings into future
interventions to prevent, treat, and eliminate this ancient and
intractable scourge.
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